SCHEMBL15090684

SCHEMBL15090684

CCCc1cc(C(=O)c2ccccc2F)n(C)c1C(=O)NC1C2CC3CC1CC(O)(C3)C2

nearest known ligand 0.45

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 19/20 0.45
HSD11B2 P80365 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15090679 0.94 HSD11B1 (0.45) HSD11B1HSD11B2
SCHEMBL15090818 0.93 HSD11B1 (0.44) HSD11B1HSD11B2
SCHEMBL15090610 0.88 HSD11B1 (0.44) HSD11B1
SCHEMBL15090860 0.87 HSD11B1 (0.45) HSD11B1HSD11B2
SCHEMBL15090514 0.86 HSD11B1 (0.43) HSD11B1
SCHEMBL15090603 0.86 HSD11B1 (0.44) HSD11B1HSD11B2
SCHEMBL15090533 0.86 HSD11B1 (0.41) HSD11B1
SCHEMBL15090583 0.84 HSD11B1 (0.47) HSD11B1HSD11B2
SCHEMBL15198851 0.84 HSD11B1 (0.46) HSD11B1HSD11B2
SCHEMBL15090530 0.84 HSD11B1 (0.46) HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US claimed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US claimed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP claimed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 HSD11B1 583/4885HSD11B2 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.